Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit

Whitfield, Robert J.; Kollias, James; Silva, Primali de; Zorbas, Helen; Maddern, Guy J.

doi:10.1111/j.1445-2197.2011.05998.x

Cited by 15 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, estimates of trastuzumab use at the time of data collection or reporting might not be reflective of current treatment patterns or guidelines. It should also be noted that several studies in patients with EBC reported findings on the basis of data from patients who were diagnosed and/or treated between 2005 and 2008 (Table 1), 23,25,30,31,36,40,41,44 which might not have captured or been sufficient to fully characterize trastuzumab use after expanded approvals for adjuvant or neoadjuvant therapy.…”

Section: Discussionmentioning

confidence: 99%

“…19 Observational studies on real-world treatment patterns in patients diagnosed with and/or treated for HER2 þ EBC between 2005 and 2015 suggest that 19.1% to 59.5% in the United States, Canada, Australia, New Zealand, United Kingdom, The Netherlands, Germany, and China did not receive neoadjuvant or adjuvant trastuzumab (Table 1). [23][24][25][30][31][32][34][35][36][37][39][40][41]44,45 Use of trastuzumab was somewhat less in patients with small ( 1 cm) and/or node-negative HER2 þ tumors, 28,30,40,41,44 in whom the benefits of adjuvant trastuzumab therapy are somewhat controversial. 7,9,10 Several studies conducted between 2006 and 2013 also suggest that older patients with HER2 þ EBC and patients with HER2 þ /hormone receptor (HR)-positive disease were less likely to receive trastuzumabbased therapy (Table 1).…”

Section: Patterns Of Use In Ebcmentioning

confidence: 99%

“…7,9,10 Several studies conducted between 2006 and 2013 also suggest that older patients with HER2 þ EBC and patients with HER2 þ /hormone receptor (HR)-positive disease were less likely to receive trastuzumabbased therapy (Table 1). 24,30,34,35,39,41 Of these patients, approximately 50% of those aged 65 years or older in the United States, 47.1% (32 patients) older than 69 years in Germany, and 67% (176 patients) older than 70 years in Australia and New Zealand did not receive trastuzumab-based therapy (Table 1). 34,35,39,41 Lesser use of trastuzumab in older patients might reflect, in part, increased comorbidities.…”

Section: Patterns Of Use In Ebcmentioning

confidence: 99%

“…24,30,34,35,39,41 Of these patients, approximately 50% of those aged 65 years or older in the United States, 47.1% (32 patients) older than 69 years in Germany, and 67% (176 patients) older than 70 years in Australia and New Zealand did not receive trastuzumab-based therapy (Table 1). 34,35,39,41 Lesser use of trastuzumab in older patients might reflect, in part, increased comorbidities. However, among women of this older age group in the United States, those who resided in impoverished neighborhoods or who were black were less likely to receive trastuzumab-based therapy (Table 1).…”

Section: Patterns Of Use In Ebcmentioning

confidence: 99%

See 3 more Smart Citations

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

Blackwell

Gligorov

Jacobs

et al. 2018

Clinical Breast Cancer

View full text Add to dashboard Cite

Trastuzumab improves survival outcomes for patients with HER2-positive (HER2) breast cancer, yet not all such women receive this important therapy. Trastuzumab was approved by the US Food and Drug Administration in 1998 and the European Medicines Agency in 2000 as treatment for HER2 metastatic breast cancer (MBC). Observational studies between 2000 and 2015 in patients with HER2 MBC suggest that nearly 12% in the United States, 27% to 54% in Europe, and 27.1% to 49.2% in China did not receive trastuzumab or any other HER2-targeted agent as first- and/or later-line for treatment of metastatic disease. In 2006, both agencies approved trastuzumab as adjuvant therapy for patients with HER2 early breast cancer (EBC). Observational studies on real-world treatment patterns for HER2 EBC between 2005 and 2015 suggest that 19.1% to 59.5% of patients across regions of North America, Europe, Australia, New Zealand, and China did not receive (neo)adjuvant trastuzumab. Data suggest that some patient subgroups, including older patients, those with HER2/hormone receptor-positive disease, and women with small and/or node-negative HER2 tumors, were less likely to receive anti-HER2 therapy. Barriers to accessing trastuzumab are multifactorial and include issues related to drug funding and high treatment costs for patients that have been reported worldwide. Herein, we review available literature on the use of, and barriers to, treatment with trastuzumab in patients with HER2 breast cancer. We also discuss how the availability of safe and effective biosimilars might increase access to trastuzumab and allow greater use of anti-HER2 therapy, potentially improving patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Patterns Of Use In Ebcmentioning

confidence: 99%

Section: Patterns Of Use In Ebcmentioning

confidence: 99%

Section: Patterns Of Use In Ebcmentioning

confidence: 99%

See 2 more Smart Citations

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

Blackwell

Gligorov

Jacobs

et al. 2018

Clinical Breast Cancer

View full text Add to dashboard Cite

show abstract

“…In our cohort, 3% of patients did not start with trastuzumab. Whitfield et al [15] reported for Australia and New Zealand that during 2006 and 2008, the percentage of breast cancers tested rose from 77% to 91%. In our cohort, only 4% of HER2 results were missing.…”

Section: Discussionmentioning

confidence: 99%

Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium

et al. 2015

View full text Add to dashboard Cite

Background. The impact of drug prescriptions in real life as opposed to strict clinical trial prescription is only rarely assessed, although it is well recognized that incorrect use may harm patients and may have a significant impact on health care resources. We investigated the use and effectiveness of adjuvant trastuzumab in daily practice compared with the effectiveness in clinical trials. Methods. We included all patients with stage I-III invasive breast cancer, irrespective of human epidermal growth factor receptor 2 (HER2) status, diagnosed in five hospitals in the southeast of The Netherlands in [2005][2006][2007]. We aimed to assess the actual use of adjuvant trastuzumab in early HER2-positive breast and its efficacy in daily practice. Results. Of 2,684 patients included, 476 (17.7%) had a HER2-positive tumor. Of these, 251 (52.7%) patients had an indication for trastuzumab treatment of which 196 (78.1%)

show abstract

Breast Pathology

Krishnamurthy¹,

Contreras²,

Albarracin³

et al. 2020

Oncological Surgical Pathology

View full text Add to dashboard Cite

Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit

Abstract: Trastuzumab-prescribing trends conform to the published guidelines. However, older patients and those with HER-2 positive, node-negative tumours >1 cm may be undertreated in some cases.

Cited by 15 publications

References 18 publications

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium

Breast Pathology

Contact Info

Product

Resources

About